Figure S2 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

Supplementary Figure 2. Activity of BBT-176 in EGFR WT and EGFR exon 20 insertion models.